MA38654B1 - Dérivés de type promédicament de triazolopyridines substituées - Google Patents

Dérivés de type promédicament de triazolopyridines substituées

Info

Publication number
MA38654B1
MA38654B1 MA38654A MA38654A MA38654B1 MA 38654 B1 MA38654 B1 MA 38654B1 MA 38654 A MA38654 A MA 38654A MA 38654 A MA38654 A MA 38654A MA 38654 B1 MA38654 B1 MA 38654B1
Authority
MA
Morocco
Prior art keywords
derivatives
prodrug type
substituted triazolopyridines
triazolopyridines
substituted
Prior art date
Application number
MA38654A
Other languages
English (en)
Inventor
Gerhard Siemeister
Antje Margret Wengner
Volker Schulze
Philip Lienau
Hans-Georg Lerchen
Ulrich Lücking
Dirk Kosemund
Michael Brüning
Detlef Stöckigt
Donald Bierer
Ursula Krenz
Ildikó Terebesi
Original Assignee
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Pharma AG filed Critical Bayer Pharma AG
Publication of MA38654B1 publication Critical patent/MA38654B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
    • C07K5/06052—Val-amino acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06086—Dipeptides with the first amino acid being basic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Cette invention concerne des dérivés de type promédicament d'inhibiteurs de kinases mps-1, des procédés pour les préparer et leur utilisation pour traiter et/ou prévenir des maladies.
MA38654A 2013-06-11 2014-06-06 Dérivés de type promédicament de triazolopyridines substituées MA38654B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP13171508 2013-06-11
PCT/EP2014/061779 WO2014198647A2 (fr) 2013-06-11 2014-06-06 Dérivés de type promédicament de triazolopyridines substituées

Publications (1)

Publication Number Publication Date
MA38654B1 true MA38654B1 (fr) 2018-11-30

Family

ID=48576905

Family Applications (1)

Application Number Title Priority Date Filing Date
MA38654A MA38654B1 (fr) 2013-06-11 2014-06-06 Dérivés de type promédicament de triazolopyridines substituées

Country Status (35)

Country Link
US (1) US9586958B2 (fr)
EP (1) EP3008062B1 (fr)
JP (1) JP2016526534A (fr)
KR (1) KR20160019492A (fr)
CN (1) CN105377848A (fr)
AP (1) AP2015008898A0 (fr)
AR (1) AR096585A1 (fr)
AU (1) AU2014280356A1 (fr)
CA (1) CA2914745A1 (fr)
CL (1) CL2015003605A1 (fr)
CR (1) CR20150659A (fr)
CU (1) CU20150176A7 (fr)
DK (1) DK3008062T3 (fr)
DO (1) DOP2015000299A (fr)
EA (1) EA201600002A1 (fr)
ES (1) ES2626790T3 (fr)
HK (1) HK1221955A1 (fr)
HR (1) HRP20170717T1 (fr)
HU (1) HUE033131T2 (fr)
IL (1) IL242847A0 (fr)
LT (1) LT3008062T (fr)
MA (1) MA38654B1 (fr)
MX (1) MX2015017119A (fr)
NI (1) NI201500176A (fr)
PE (1) PE20160156A1 (fr)
PH (1) PH12015502746A1 (fr)
PL (1) PL3008062T3 (fr)
PT (1) PT3008062T (fr)
RS (1) RS56034B1 (fr)
SG (1) SG11201509858QA (fr)
SI (1) SI3008062T1 (fr)
TN (1) TN2015000545A1 (fr)
UY (1) UY35610A (fr)
WO (1) WO2014198647A2 (fr)
ZA (1) ZA201508868B (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA41136A (fr) * 2014-12-09 2017-10-17 Bayer Pharma AG Composés pour le traitement d'un cancer
PT3283642T (pt) 2015-04-17 2024-01-02 Crossfire Oncology Holding B V Biomarcadores de prognóstico para quimioterapia inibidora de ttk
MX2018011831A (es) 2016-04-04 2019-02-13 Chemocentryx Inc Antagonistas solubles de receptor de c5aa(c5ar).
CA3241111A1 (fr) * 2021-12-15 2023-06-22 Heidi Lane Methodes de traitement de maladies neoplasiques

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69736711T2 (de) 1996-08-28 2007-09-20 Pfizer Inc. Substituierte 6,5-heterobicyclische-derivate
IL133007A (en) 1997-05-28 2005-06-19 Aventis Pharma Inc Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56lck tyrosine kinases
US6514989B1 (en) 2001-07-20 2003-02-04 Hoffmann-La Roche Inc. Aromatic and heteroaromatic substituted 1,2,4-triazolo pyridine derivatives
JP2004346016A (ja) 2003-05-22 2004-12-09 Otsuka Chemical Co Ltd トリフルオロメチルキノキサリン化合物、その製造方法、及び有害生物防除剤
JP4499721B2 (ja) 2003-06-30 2010-07-07 ヒフ バイオ，インク． 化合物、組成物および方法
EP1799680A2 (fr) 2004-10-07 2007-06-27 Warner-Lambert Company LLC Derives de triazolopyridine comme agents antibacteriens
US20070049591A1 (en) 2005-08-25 2007-03-01 Kalypsys, Inc. Inhibitors of MAPK/Erk Kinase
US20070078136A1 (en) 2005-09-22 2007-04-05 Bristol-Myers Squibb Company Fused heterocyclic compounds useful as kinase modulators
US7723336B2 (en) 2005-09-22 2010-05-25 Bristol-Myers Squibb Company Fused heterocyclic compounds useful as kinase modulators
WO2007065010A2 (fr) 2005-12-02 2007-06-07 Hif Bio, Inc. Composes anti-angiogenese
EA200870592A1 (ru) 2006-05-31 2009-08-28 Галапагос Н.В. Триазолопиразиновые соединения, пригодные для лечения дегенеративных и воспалительных заболеваний
US20100075947A1 (en) 2006-08-16 2010-03-25 Exelixis, Inc. Methods of Using PI3K and MEK Modulators
CN103641829A (zh) 2006-08-30 2014-03-19 塞尔佐姆有限公司 作为激酶抑制剂的三唑衍生物
PE20090288A1 (es) 2007-05-10 2009-04-03 Smithkline Beecham Corp Derivados de quinoxalina como inhibidores de la pi3 quinasa
CN101801966A (zh) 2007-07-18 2010-08-11 诺瓦提斯公司 双环杂芳基化合物和它们作为激酶抑制剂的用途
JP2010535804A (ja) 2007-08-09 2010-11-25 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー Ｐｉ３キナーゼ阻害薬としてのキノキサリン誘導体
MX2010002115A (es) 2007-08-23 2010-06-01 Aztrazeneca Ab 2-anilinopurin-8-onas como inhibidores de ttk/mps1 para el tratamiento de trastornos .proliferativos.
KR20100075881A (ko) 2007-08-31 2010-07-05 메르크 세로노 에스. 에이. 트리아졸로피리딘 화합물 및 ａｓｋ 저해제로서 이의 용도
GB0719803D0 (en) 2007-10-10 2007-11-21 Cancer Rec Tech Ltd Therapeutic compounds and their use
EP2222674B8 (fr) 2007-11-27 2016-01-06 Cellzome Limited Amino triazoles en tant qu'inhibiteurs pi3k
US8415376B2 (en) 2008-05-30 2013-04-09 Amgen Inc. Inhibitors of PI3 kinase
TWI491610B (zh) 2008-10-09 2015-07-11 必治妥美雅史谷比公司 作為激酶抑制劑之咪唑并嗒腈
WO2010092015A1 (fr) 2009-02-10 2010-08-19 Cellzome Limited Dérivés d'urée-triazolo[1,5-a]pyridine en tant qu'inhibiteurs de pi3k
EA201101188A1 (ru) 2009-02-13 2012-04-30 Фовеа Фармасьютикалз [1,2,4]триазоло[1,5-а]пиридины в качестве ингибиторов киназы
CN102413831B (zh) 2009-04-29 2014-06-04 拜耳知识产权有限责任公司 取代的咪唑并喹喔啉
TW201107329A (en) 2009-07-30 2011-03-01 Oncotherapy Science Inc Fused imidazole derivative having ttk inhibitory action
CN102596932A (zh) 2009-09-04 2012-07-18 拜耳医药股份有限公司 作为酪氨酸苏氨酸激酶抑制剂的取代氨基喹喔啉
EP2343295A1 (fr) * 2009-11-30 2011-07-13 Bayer Schering Pharma AG Dérivés de triazolopyridine
EP2343294A1 (fr) 2009-11-30 2011-07-13 Bayer Schering Pharma AG Triazolopyridines substituées
EP2343297A1 (fr) * 2009-11-30 2011-07-13 Bayer Schering Pharma AG Triazolopyridines
EP2523949B1 (fr) 2010-01-15 2014-08-20 Janssen Pharmaceuticals Inc. Nouveaux dérivés de triazole en tant que modulateurs de la secrétase gamma
US20110190269A1 (en) 2010-02-01 2011-08-04 Karlheinz Baumann Gamma secretase modulators
UY33452A (es) * 2010-06-16 2012-01-31 Bayer Schering Pharma Ag Triazolopiridinas sustituidas
TWI541243B (zh) 2010-09-10 2016-07-11 拜耳知識產權公司 經取代咪唑并嗒
AU2012244859B2 (en) 2011-04-21 2017-06-08 Bayer Intellectual Property Gmbh Triazolopyridines
UA112096C2 (uk) * 2011-12-12 2016-07-25 Байєр Інтеллектуал Проперті Гмбх Заміщені триазолопіридини та їх застосування як інгібіторів ttk
ES2605946T3 (es) 2012-03-14 2017-03-17 Bayer Intellectual Property Gmbh Imidazopiridazinas sustituidas
EP2872506A1 (fr) * 2012-07-10 2015-05-20 Bayer Pharma Aktiengesellschaft Procédé de préparation de triazolopyridines substituées
AR096469A1 (es) * 2013-06-06 2015-12-30 Bayer Pharma AG Composiciones farmacéuticas que comprenden compuestos del tipo triazolpiridinas
CN105431435A (zh) * 2013-06-07 2016-03-23 拜耳制药股份公司 具有作为mps-1抑制剂的活性的取代的三唑并吡啶类
BR112015030774A2 (pt) * 2013-06-10 2017-07-25 Bayer Pharma AG novos compostos para o tratamento de câncer
CA2914742A1 (fr) * 2013-06-11 2014-12-18 Bayer Pharma Aktiengesellschaft Transferts allies a des cellules cooperantes configures pour fournir la transmission/reception multipoint coordonnee

Also Published As

Publication number Publication date
HK1221955A1 (zh) 2017-06-16
ZA201508868B (en) 2017-08-30
EP3008062A2 (fr) 2016-04-20
SG11201509858QA (en) 2015-12-30
CL2015003605A1 (es) 2016-06-24
WO2014198647A2 (fr) 2014-12-18
CA2914745A1 (fr) 2014-12-18
RS56034B1 (sr) 2017-09-29
ES2626790T3 (es) 2017-07-26
TN2015000545A1 (en) 2017-04-06
US20160207915A1 (en) 2016-07-21
DK3008062T3 (en) 2017-06-12
EA201600002A1 (ru) 2016-06-30
WO2014198647A3 (fr) 2015-02-05
LT3008062T (lt) 2017-06-12
NI201500176A (es) 2016-01-06
AR096585A1 (es) 2016-01-20
CR20150659A (es) 2016-01-29
PT3008062T (pt) 2017-06-07
PH12015502746A1 (en) 2016-03-21
US9586958B2 (en) 2017-03-07
AP2015008898A0 (en) 2015-12-31
PL3008062T3 (pl) 2017-08-31
MX2015017119A (es) 2016-04-06
DOP2015000299A (es) 2016-03-15
HRP20170717T1 (hr) 2017-07-28
PE20160156A1 (es) 2016-04-20
IL242847A0 (en) 2016-02-01
KR20160019492A (ko) 2016-02-19
SI3008062T1 (sl) 2017-06-30
CN105377848A (zh) 2016-03-02
UY35610A (es) 2015-01-30
HUE033131T2 (en) 2017-11-28
AU2014280356A1 (en) 2015-12-24
EP3008062B1 (fr) 2017-04-05
JP2016526534A (ja) 2016-09-05
CU20150176A7 (es) 2016-05-30

Similar Documents

Publication Publication Date Title
PH12018500041A1 (en) Substituted aza compoounds as irak-4 inhibitors
MX2019001125A (es) Inhibidores de cinasa macrociclica.
PH12016501898B1 (en) Quinoxaline derivatives useful as fgfr kinase modulators
MA38347A1 (fr) Dérivés de pyrrolo[2,3-d]pyrimidine en tant qu'inhibiteurs de janus kinases (jak)
EA201792619A1 (ru) Нафтиридиновые соединения в качестве ингибиторов jak киназы
PH12015502788A1 (en) Antibody formulations and methods
EA202090291A3 (ru) Производные бипиразола в качестве ингибиторов jak
MX2015013481A (es) Compuestos heterociclicos fusionados como inhibidores de proteina quinasa.
MX2015011984A (es) Inhibidores de bromodominio de dihidro-pirrolopiridinona.
WO2015050989A3 (fr) Composés macrocycliques destinés au traitement de maladies prolifératives
MX2016002544A (es) Compuestos utiles como inmunomoduladores.
EA201592024A1 (ru) Замещенные 5-(3,5-диметилизоксазол-4-ил)-индолин-2-оны
EA201591420A1 (ru) Гетероарильные соединения и их применение
MX2016008110A (es) Derivados de pirazol como inhibidores de la cinasa de cremallera de leucina dual (dlk) y usos de los mismos.
MX2018003186A (es) Derivados de 8-[6-[3-(amino)propoxi]-3-piridil]1-isopropilimidazo[ 4,5-c]quinolin-2-ona como moduladores selectivos de la cinasa de la ataxia telangiectasia mutada (atm) para el tratamiento del cancer.
MX2015009270A (es) Pirazoles sustituidos en posicion 3 y uso de los mismos como inhibidores de la cinasa cremallera de leucinas dual (dlk).
GEP20196961B (en) 4-oxo-3,4-dihydro-1,2,3 -benzotriazines modulators of gpr139
EA201591794A1 (ru) Макроциклические ингибиторы соль-индуцируемых киназ
EA201691674A1 (ru) 1,2-замещенные циклопентаны в качестве антагонистов рецептора орексина
EA201690523A1 (ru) Триазолопиридины, композиции и способы их применения
WO2018218197A3 (fr) Inhibiteurs de la kinase atr à base de tétrahydropyrido[4,3-d]pyrimidine
MA38654B1 (fr) Dérivés de type promédicament de triazolopyridines substituées
BR112015020834A2 (pt) novos derivados hidroquinolina-2-ona como inibidores de aldosterona sintetase (cyp1 1 b2 ou cyp1 1 b1)
EA201692227A1 (ru) Производные сложных аминоэфиров
MX367707B (es) Composiciones para uso en la prevencion y el tratamiento de enfermedades neurodegenerativas y dolor.